TY - JOUR
T1 - Anatomy of the cervicomental region
T2 - Insights from an anatomy laboratory and roundtable discussion
AU - Kenkel, Jeffrey M.
AU - Jones, Derek H.
AU - Fagien, Steven
AU - Glaser, Dee Anna
AU - Monheit, Gary D.
AU - Stauffer, Karen
AU - Sykes, Jonathan M.
N1 - Publisher Copyright:
© 2016 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016
Y1 - 2016
N2 - In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was approved as a first-inclass injectable drug for reduction of submental fat. Use of a pharmacologic/injectable therapy within the submental region requires a thorough understanding of cervicomental anatomy to ensure proper injection technique and safe administration. To this end, an anatomy laboratory was conducted to review key external landmarks and important internal anatomic structures that characterize the lower face and anterior neck. External landmarks that define the boundaries of the cervicomental and submental regions were identified including the inferior mandibular border, the anterior border of the sternocleidomastoid muscle, the antegonial notch, the submental crease, the thyroid notch, and the hyoid bone. Relevant internal anatomic structures, including preplatysmal submental fat (the target tissue for ATX-101) and the platysma muscle as well as critical neurovascular and glandular tissues were revealed by dissection. Of particular interest was the marginal mandibular branch of the facial nerve because it typically courses along the inferior mandibular border near the proposed treatment area for ATX-101.
AB - In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was approved as a first-inclass injectable drug for reduction of submental fat. Use of a pharmacologic/injectable therapy within the submental region requires a thorough understanding of cervicomental anatomy to ensure proper injection technique and safe administration. To this end, an anatomy laboratory was conducted to review key external landmarks and important internal anatomic structures that characterize the lower face and anterior neck. External landmarks that define the boundaries of the cervicomental and submental regions were identified including the inferior mandibular border, the anterior border of the sternocleidomastoid muscle, the antegonial notch, the submental crease, the thyroid notch, and the hyoid bone. Relevant internal anatomic structures, including preplatysmal submental fat (the target tissue for ATX-101) and the platysma muscle as well as critical neurovascular and glandular tissues were revealed by dissection. Of particular interest was the marginal mandibular branch of the facial nerve because it typically courses along the inferior mandibular border near the proposed treatment area for ATX-101.
UR - http://www.scopus.com/inward/record.url?scp=85014883431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014883431&partnerID=8YFLogxK
U2 - 10.1097/DSS.0000000000000896
DO - 10.1097/DSS.0000000000000896
M3 - Article
C2 - 27787268
AN - SCOPUS:85014883431
SN - 1076-0512
VL - 42
SP - S282-S287
JO - Dermatologic Surgery
JF - Dermatologic Surgery
ER -